SlideShare ist ein Scribd-Unternehmen logo
1 von 34
Downloaden Sie, um offline zu lesen
CURRENT AND FUTURE OPTIONS FOR
THE TREATMENT OF DYSKINESIA
AND MOTOR FLUCTUATIONS IN
PARKINSON’S DISEASE
Guided by:
Dr. Suneela Dhaneshwar
Professor

Presented by:
Latika Budhalakoti
M. Pharm
(Pharmaceutical
Chemistry)

Department of Pharmaceutical Chemistry
Bharati Vidyapeeth Deemed University
Poona College of Pharmacy
Erandwane, Pune-411038
1


Parkinson’s Disease (PD)
A degenerative and progressive disorder.



Associated with neurological consequences of
decreased dopamine levels produced by the
basal ganglia (substantia nigra).



Dopamine (DOPA) is a neurotransmitter found
in the neural synapses in the brain.



Initiates movement,
expression.

speech

and

self2
Role of substantia nigra in Parkinson's disease.

3
Causes
 Environmental – toxins.
 Free Radicals – there is a increase in post-

mortem brain sections.
 Aging – age related decline in dopamine

production.
 Genetic

– possible, no single gene

identified.
4
Consequences of dopamine reductions

5
Drugs for treatment of Parkinson’s disease


The Drugs:
 Dopaminergic drugs (improving dopamine functioning)
○ Dopamine precursor- levodopa.
○ Dopamine receptor agonists- apomorphine.
○ NMDA receptor antagonist- amantadine.
 Selective monoamine oxidase B inhibitors- selegiline.
 Catechol-O-methyltransferase inhibitors- entacapone.

 Antimuscarinic drugs (Ach inhibitors)-biperiden.
6
Sites of action of drugs used to treat
Parkinson's disease.
+
carbidopa

Therapeutic effect
7
Administration of Levodopa

8
Role of levodopa in Parkinson

9
Limitations on use of levodopa







The response to L- DOPA changes during the
progression.
Thus total dosage and the total doses per day
increases after intiation.
Many patients exhibit abnormal involuntary
movements (dyskinesia) and motor fluctuations.
The use of levodopa may stimulate dopa receptors
that can cause hallucinations, paranoia and
confusion.
L-DOPA is unable to halt the progresssion of
neurodegeneration.
10
Overcoming levodopa limitations


The

risk

of

dyskinesia

and

motor

fluctuations can be minimised
o

By improving methods of L-DOPA delivery.

o

By developing non - dopaminergic treatment
methods.

11


In this article the current clinical management of
motor complications are mentioned-

o

By peroral drug treatment.

o

By continuous dopaminergic stimulation or deep
brain stimulation.

12
Peroral drug therapy






The Dopamine agonists (DA) act on same
receptors D3/ D4 but have longer duration of
action than L-DOPA.
The initial treatment may reduce dyskinesia
and motor fluctuations.
The Dopamine agonists added to l-dopa
reduces time spent in “off condition”.
Dopamine agonist is useful in advance
condition of parkinson and motor fluctuations.
13
Currently used DA in Parkinson’s disease

14


Dopamine agonists have disease modifying /
neuroprotective effects.



On use of some biomarkers of presynaptic DA
fibre it was found that there was slow loss of
signal in patients treated than in l-dopa.

o

DOPAMINERGIC DRUG TREATMANT
Includes COMT INHIBITORS, MAO-B
INHIBITORS,
NMDA
RECEPTOR
ANTAGONISTS.



15
 COMT






INHIBITORS

Are administered with l-dopa in patients with
motor fluctuations.
Prolongs the effect of single dose.
Reduces the time spent in off state.
Examples are tolcapone, entacapone.
Side effect- it may cause hepatotoxicity.
Tolcapone

16
MAO- B Inhibitors







Rasagiline
When added to LDOPA.
Slows development
of syptoms.
Reduces l-dopa need.
Reduces incidence of
dyskinesias.
Has disease
modifying role.

Rasagiline
17
NMDA Receptor antagonists


Amantadine



Reduces l-dopa
induced dyskinesia.
It has potential to
improve congenitive
functions.
It is an antidyskinetic
agent.





Amantadine

18


The NMDA receptor is the only non
dopaminergic drug currently used for l-dopa
induced dyskinesia.



The NR2B subunit of the NMDA receptor is
expressed in striatal neurons.



NMDA receptor antagonists that interact with
NR2B subunit have shown to prevent
development of dyskinesia in non human primate
of parkinson disease.
19
Continuous Dopaminergic stimulation (CDS)


Severe motor fluctuations are controlled by
continuous dopaminergic stimulation.
 Three types of interventions currently found
effective areo Continuous deudenal l-dopa administration.
o Subcutaneous apomorphine infusion.
o Deep brain stimulation.
o Continuous occupancy of DOPA receptors by
long acting DOPA agonists.
20



o

o


The intravenous administration of l-dopa for
longer time was proved to be difficult.
The first intraduodenal l-dopa infusion were
published in 1986.
L-DOPA-Carbidopa Intestinal Gel
Combination of l-dopa(20mg/ml) and carbidopa
and (5mg/ml).
Is a pseudoplastic gel delivered through infusion
pumps.
LCIG infusion results in stabilization of both
plasma l-dopa concentation and clinical status.
21


Reduction of motor fluctuations and time spent in
off.



The mean dyskinesia severity was reduced by 90%
over a period of 6 months of LICG therapy.



LCIG

infusion

improves

non

motor

aspects

(urological, git problems) of parkinson disease.


Initial duodenal LCIG infusion given only during
day.
22
Adverse events of LCIG infusion


Dislocation or occlusion of duodenal catheter.



Leakage in the infusion system.



Problems related to PEG establishment.

23
Apomorphine treatment


Apomorphine (s.c.) administration along with ldopa exerts strongest on Parkinson disease.



It seems to be stable over long term follow up.



The probem associated with apomorphine infusion
is formation of s.c. nodules.



The psychotic complications is not high with
apomorphine than on dopaminergic therapy.
24
Transdermal drug delivery


Recently developed method tried on DA agonists
(rotigotine) to provide continuous drug supply
and to treat advance stage of disease.
 ADVANTAGES OF PATCH DELIVERY
o When peroral delivery is contraindicated due to
some GIT dysfunction.
o In patients with therapy compliance problems.
o In patients with parkinson related sleep
disturbances in late night/early morning.
 Side effects of rotigotine are skin reaction.
 Lisuride and apomorphine are investigated to be
given transdermally.
25
Current surgical management of motor
complications


Neurosurgery, including lesional surgery and deep
brain stimulation are effective in advance parkinson.
 Compared to deep brain stimulation the lesional
surgery is associated with complications.
 DEEP BRAIN STIMULATION (DBS)
o Macromolecules are stereotactically implanted in brain
part and is connected to electrical stimulator positioned
subcutaneously in sub clavicular region.
o Two brain nuclei most commonly used as target for
DBS are globus pallidus and sub thalamic nucleus.
26
Surgical interventions for
Parkinson’s disease


Surgical intervention and description of procedureo Pallidotomy This involves the use of an electric probe
to destroy a small portion of the brain that is overactive
and is thought to cause the symptoms of PD.
o Thalamotomy The procedure involves the removal of
the thalamus in the brain, which is responsible for
involuntary movements, thus destroying it prevents
involuntary movements. This procedure
is rarely performed and is only effective in providing
relief from tremors.
27


Thalamic stimulation Involves the insertion of an
electrode wire into the thalamus, the other end of
which is connected to a pulse generator placed under
the skin in the thorax.
o The advantage is that it can produce the benefit of
thalamotomy without causing incision of the skin and
has demonstrated efficacy in the management of
tremor in PD.
 Deep brain stimulation (DBS) An alternative
procedure used to destroy small regions of the brain.
A thin electrode implanted into the brain prevents
transmission of impulses for involuntary movements.
28
Future treatment of Parkinson by gene therapy


By implanting genetically modified cells (ex
vivo gene transfer).



By viral vector mediated gene delivery to
resident cells( in vivo gene transfer).

29
Gene therapy to provide continuous
dopamine stimulation

30
Treatment targeting non dopaminergic systems




o

The addition of non dopaminergic drugs to ldopa prevents and treats motor complications.
Reduces severity of peak dose dyskinesia.
Prolong the time spent in “on” condition upon ldopa dosing.
GLUTAMATE RECEPTORS
Alter the synaptic and molecular level striatal
neurons that occurs in dyskinetic animals.

31
Tamarind used to treat Parkinson’s
disease


A compound from tamarind tree help spur the growth of
damaged brain andspinal cord nerve cells, which
characterises Parkinson’s.
 Xyloglucon , the extract from tamarind seeds. It’s a
gel kind which will be helpful in regenerating the
nerve cells.
 On injection creates a favourable environment in the
body to regenerate the cells. Thus in the human beings
it is helpful to the production of Astrocytes which are
responsible for the regeneration of the cells.
32
Conclusion








Parkinson’s is a disease of the basal ganglia as
well as neurotransmitter deficiencies.
Significant advances have been made in optimizing
strategies for continuous dopa stimulation in
Parkinson’s.
Continuous dopa stimulaion does not worsen
condition of patient and even improve non motor
features.
Novel approaches to CDS based on gene therapy
are being explored in parkinson patients.
The results of this study will provide guidelines for
designing clinical trials of antidyskinetic treatment.
33
References


Mercuri, N . B.; Bernardi, G. The magic of l-dopa:
why is it the gold standard Parkinson’s disease
therapy? Trends Pharmacol. Sci., 2005, 26, 341-344.
 Hoehn, M.M. Parkinson’s disease: progression and
mortality. Adv. Neurol., 1987 , 45 , 457-461.
 Ahlskog, J . E; Muenter , M .D. Frequency of
levodopa-related dyskinesias and motor fluctuations
as estimated from the cumulative literature. Mov.
Discord., 2001 ,16, 448-458.
 Schrag, A. Psychiatric aspects of Parkinson’s diseasean update. J. Neurol., 2004, 251, 795-804.
34

Weitere ähnliche Inhalte

Was ist angesagt?

Management of advanced parkinson’s disease
Management of advanced parkinson’s diseaseManagement of advanced parkinson’s disease
Management of advanced parkinson’s diseaseAhmed Koriesh
 
Parkinson’S Disease
Parkinson’S DiseaseParkinson’S Disease
Parkinson’S Diseasemsrpt
 
Pharmacotherapy of parkinsons disease
Pharmacotherapy of parkinsons diseasePharmacotherapy of parkinsons disease
Pharmacotherapy of parkinsons diseaseQudsia Nuzhat
 
Pathophysiology of parkinsons disease
Pathophysiology of parkinsons diseasePathophysiology of parkinsons disease
Pathophysiology of parkinsons diseaseNem kumar Jain
 
Parkinson’S Disease
Parkinson’S DiseaseParkinson’S Disease
Parkinson’S Diseasemarlasavage
 
Recent advances in neurodegenerative disorders
Recent advances in neurodegenerative disordersRecent advances in neurodegenerative disorders
Recent advances in neurodegenerative disordersDr. Siddhartha Dutta
 
non motor manifestation of parkinson disease
non motor manifestation of parkinson diseasenon motor manifestation of parkinson disease
non motor manifestation of parkinson diseaseOsama Ragab
 
Antiparkinsonian drugs ppts 1
Antiparkinsonian drugs ppts 1Antiparkinsonian drugs ppts 1
Antiparkinsonian drugs ppts 1drnutan goswami
 
Parkinsons disease V Pharm.D
Parkinsons disease V Pharm.DParkinsons disease V Pharm.D
Parkinsons disease V Pharm.DDr.Sohel Memon
 
Parkinson’S Disease
Parkinson’S DiseaseParkinson’S Disease
Parkinson’S Diseaseguest27ee33
 
PARKINSON'S DISEASE And pathophysiology .pdf by SMH.pdf
PARKINSON'S DISEASE And pathophysiology .pdf by SMH.pdfPARKINSON'S DISEASE And pathophysiology .pdf by SMH.pdf
PARKINSON'S DISEASE And pathophysiology .pdf by SMH.pdfwajidullah9551
 
Parkinson's disease n management
Parkinson's disease n managementParkinson's disease n management
Parkinson's disease n managementDr. Rupendra Bharti
 
Parkinson's Disease - Neurology
Parkinson's Disease - NeurologyParkinson's Disease - Neurology
Parkinson's Disease - NeurologyNadia Shams
 
ANTI ANXIETY AGENTS / DRUGS USED IN THE TREATMENT OF ANXIETY
ANTI ANXIETY AGENTS / DRUGS USED IN THE TREATMENT OF ANXIETYANTI ANXIETY AGENTS / DRUGS USED IN THE TREATMENT OF ANXIETY
ANTI ANXIETY AGENTS / DRUGS USED IN THE TREATMENT OF ANXIETYKameshwaran Sugavanam
 
Parkinson's Disease [Advanced Pharmacology]
Parkinson's Disease [Advanced Pharmacology]Parkinson's Disease [Advanced Pharmacology]
Parkinson's Disease [Advanced Pharmacology]Megh Vithalkar
 

Was ist angesagt? (20)

Management of advanced parkinson’s disease
Management of advanced parkinson’s diseaseManagement of advanced parkinson’s disease
Management of advanced parkinson’s disease
 
Parkinson’S Disease
Parkinson’S DiseaseParkinson’S Disease
Parkinson’S Disease
 
Parkinson s disease
Parkinson s diseaseParkinson s disease
Parkinson s disease
 
Pharmacotherapy of parkinsons disease
Pharmacotherapy of parkinsons diseasePharmacotherapy of parkinsons disease
Pharmacotherapy of parkinsons disease
 
Pathophysiology of parkinsons disease
Pathophysiology of parkinsons diseasePathophysiology of parkinsons disease
Pathophysiology of parkinsons disease
 
Parkinson's diseases
Parkinson's diseasesParkinson's diseases
Parkinson's diseases
 
Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 
Parkinson’S Disease
Parkinson’S DiseaseParkinson’S Disease
Parkinson’S Disease
 
Recent advances in neurodegenerative disorders
Recent advances in neurodegenerative disordersRecent advances in neurodegenerative disorders
Recent advances in neurodegenerative disorders
 
Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 
Parkinson's Disease
Parkinson's DiseaseParkinson's Disease
Parkinson's Disease
 
non motor manifestation of parkinson disease
non motor manifestation of parkinson diseasenon motor manifestation of parkinson disease
non motor manifestation of parkinson disease
 
Antiparkinsonian drugs ppts 1
Antiparkinsonian drugs ppts 1Antiparkinsonian drugs ppts 1
Antiparkinsonian drugs ppts 1
 
Parkinsons disease V Pharm.D
Parkinsons disease V Pharm.DParkinsons disease V Pharm.D
Parkinsons disease V Pharm.D
 
Parkinson’S Disease
Parkinson’S DiseaseParkinson’S Disease
Parkinson’S Disease
 
PARKINSON'S DISEASE And pathophysiology .pdf by SMH.pdf
PARKINSON'S DISEASE And pathophysiology .pdf by SMH.pdfPARKINSON'S DISEASE And pathophysiology .pdf by SMH.pdf
PARKINSON'S DISEASE And pathophysiology .pdf by SMH.pdf
 
Parkinson's disease n management
Parkinson's disease n managementParkinson's disease n management
Parkinson's disease n management
 
Parkinson's Disease - Neurology
Parkinson's Disease - NeurologyParkinson's Disease - Neurology
Parkinson's Disease - Neurology
 
ANTI ANXIETY AGENTS / DRUGS USED IN THE TREATMENT OF ANXIETY
ANTI ANXIETY AGENTS / DRUGS USED IN THE TREATMENT OF ANXIETYANTI ANXIETY AGENTS / DRUGS USED IN THE TREATMENT OF ANXIETY
ANTI ANXIETY AGENTS / DRUGS USED IN THE TREATMENT OF ANXIETY
 
Parkinson's Disease [Advanced Pharmacology]
Parkinson's Disease [Advanced Pharmacology]Parkinson's Disease [Advanced Pharmacology]
Parkinson's Disease [Advanced Pharmacology]
 

Andere mochten auch (20)

Parkinson’s disease
Parkinson’s diseaseParkinson’s disease
Parkinson’s disease
 
Parkinson Mestrado Universidade Estadual de Londrina
Parkinson Mestrado Universidade Estadual de LondrinaParkinson Mestrado Universidade Estadual de Londrina
Parkinson Mestrado Universidade Estadual de Londrina
 
Parkinson's disease
Parkinson's disease Parkinson's disease
Parkinson's disease
 
Parkinson, enfoque geriátrico
Parkinson, enfoque geriátricoParkinson, enfoque geriátrico
Parkinson, enfoque geriátrico
 
Enfermedad de Parkinson
Enfermedad de ParkinsonEnfermedad de Parkinson
Enfermedad de Parkinson
 
Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 
Parkinson disease with Pharmacotherapy
Parkinson disease with PharmacotherapyParkinson disease with Pharmacotherapy
Parkinson disease with Pharmacotherapy
 
Pharmacology of dopamine
Pharmacology of dopaminePharmacology of dopamine
Pharmacology of dopamine
 
Parkinson Disease
Parkinson DiseaseParkinson Disease
Parkinson Disease
 
Pharmacology - Parkinsonism
Pharmacology - ParkinsonismPharmacology - Parkinsonism
Pharmacology - Parkinsonism
 
Parkinson's Disease
Parkinson's DiseaseParkinson's Disease
Parkinson's Disease
 
Alzeihmer disease
Alzeihmer diseaseAlzeihmer disease
Alzeihmer disease
 
Dementia_Rajib
Dementia_RajibDementia_Rajib
Dementia_Rajib
 
Parkinson powerpoint 2 new
Parkinson powerpoint 2 newParkinson powerpoint 2 new
Parkinson powerpoint 2 new
 
Parkinson by amir
Parkinson by amirParkinson by amir
Parkinson by amir
 
PSP
PSPPSP
PSP
 
Mdf information
Mdf informationMdf information
Mdf information
 
Parkinsons disease
Parkinsons diseaseParkinsons disease
Parkinsons disease
 
Msa
MsaMsa
Msa
 
Parkinsons mn
Parkinsons mnParkinsons mn
Parkinsons mn
 

Ähnlich wie Presentation parkinson

Parkinson.pptx
Parkinson.pptxParkinson.pptx
Parkinson.pptxSaishDalvi
 
Recent advances in parkinsonism
Recent advances in parkinsonismRecent advances in parkinsonism
Recent advances in parkinsonismDr Nikita Ingale
 
Parkinson's disease
Parkinson's diseaseParkinson's disease
Parkinson's diseaseSudharSan43
 
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptx
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptxRECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptx
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptxashharnomani
 
Anti parkinsonian drug ppt
Anti parkinsonian drug pptAnti parkinsonian drug ppt
Anti parkinsonian drug pptHIMANSHUKUMAR822
 
Nanomedicine in Parkinson disease.pptx
Nanomedicine in Parkinson disease.pptxNanomedicine in Parkinson disease.pptx
Nanomedicine in Parkinson disease.pptxmnadeemalvi
 
Parkinson's disease
Parkinson's diseaseParkinson's disease
Parkinson's diseaseMerin Babu
 
Treatment of Parkinsonism.pptx
Treatment of Parkinsonism.pptxTreatment of Parkinsonism.pptx
Treatment of Parkinsonism.pptxFarazaJaved
 
Pharmacology of antiparkinsons drug
Pharmacology of antiparkinsons drugPharmacology of antiparkinsons drug
Pharmacology of antiparkinsons drugAshviniGovande
 
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT Srinitha Busam
 
Emerging Somatic Therapies for the Addicted Patient
Emerging Somatic Therapies for the Addicted PatientEmerging Somatic Therapies for the Addicted Patient
Emerging Somatic Therapies for the Addicted PatientBrendan Quinn
 
movement.ppt
movement.pptmovement.ppt
movement.pptkireeti8
 
Management of parkinsons disease
Management of parkinsons diseaseManagement of parkinsons disease
Management of parkinsons diseasesadaf89
 
Antiparkinsonian drugs_Adarsh.ppt
Antiparkinsonian drugs_Adarsh.pptAntiparkinsonian drugs_Adarsh.ppt
Antiparkinsonian drugs_Adarsh.pptRashmiShah46
 

Ähnlich wie Presentation parkinson (20)

Parkinson.pptx
Parkinson.pptxParkinson.pptx
Parkinson.pptx
 
Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 
Recent advances in parkinsonism
Recent advances in parkinsonismRecent advances in parkinsonism
Recent advances in parkinsonism
 
Antiparkinson drugs
Antiparkinson drugsAntiparkinson drugs
Antiparkinson drugs
 
Parkinson's disease
Parkinson's diseaseParkinson's disease
Parkinson's disease
 
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptx
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptxRECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptx
RECENT ADVANCES IN THE TREATMENT OF PARKINSON’S DISEASE.pptx
 
Anti parkinsonian drug ppt
Anti parkinsonian drug pptAnti parkinsonian drug ppt
Anti parkinsonian drug ppt
 
Antiparkinsonian drugs
Antiparkinsonian drugsAntiparkinsonian drugs
Antiparkinsonian drugs
 
Nanomedicine in Parkinson disease.pptx
Nanomedicine in Parkinson disease.pptxNanomedicine in Parkinson disease.pptx
Nanomedicine in Parkinson disease.pptx
 
Parkinson's disease
Parkinson's diseaseParkinson's disease
Parkinson's disease
 
chapter 16
chapter 16chapter 16
chapter 16
 
Parkinsonism
ParkinsonismParkinsonism
Parkinsonism
 
Treatment of Parkinsonism.pptx
Treatment of Parkinsonism.pptxTreatment of Parkinsonism.pptx
Treatment of Parkinsonism.pptx
 
Pharmacology of antiparkinsons drug
Pharmacology of antiparkinsons drugPharmacology of antiparkinsons drug
Pharmacology of antiparkinsons drug
 
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
PARKINSONS DISEASE MEDICAL TREATMENT AND PHYSIOTHERAPY MANAGEMENT
 
Antiparkinsonian Drugs
Antiparkinsonian DrugsAntiparkinsonian Drugs
Antiparkinsonian Drugs
 
Emerging Somatic Therapies for the Addicted Patient
Emerging Somatic Therapies for the Addicted PatientEmerging Somatic Therapies for the Addicted Patient
Emerging Somatic Therapies for the Addicted Patient
 
movement.ppt
movement.pptmovement.ppt
movement.ppt
 
Management of parkinsons disease
Management of parkinsons diseaseManagement of parkinsons disease
Management of parkinsons disease
 
Antiparkinsonian drugs_Adarsh.ppt
Antiparkinsonian drugs_Adarsh.pptAntiparkinsonian drugs_Adarsh.ppt
Antiparkinsonian drugs_Adarsh.ppt
 

Kürzlich hochgeladen

How to Send Emails From Odoo 17 Using Code
How to Send Emails From Odoo 17 Using CodeHow to Send Emails From Odoo 17 Using Code
How to Send Emails From Odoo 17 Using CodeCeline George
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptxmary850239
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...Nguyen Thanh Tu Collection
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfYu Kanazawa / Osaka University
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesCeline George
 
10 Topics For MBA Project Report [HR].pdf
10 Topics For MBA Project Report [HR].pdf10 Topics For MBA Project Report [HR].pdf
10 Topics For MBA Project Report [HR].pdfJayanti Pande
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.raviapr7
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.EnglishCEIPdeSigeiro
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17Celine George
 
KARNAADA.pptx made by - saransh dwivedi ( SD ) - SHALAKYA TANTRA - ENT - 4...
KARNAADA.pptx  made by -  saransh dwivedi ( SD ) -  SHALAKYA TANTRA - ENT - 4...KARNAADA.pptx  made by -  saransh dwivedi ( SD ) -  SHALAKYA TANTRA - ENT - 4...
KARNAADA.pptx made by - saransh dwivedi ( SD ) - SHALAKYA TANTRA - ENT - 4...M56BOOKSTORE PRODUCT/SERVICE
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17Celine George
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...raviapr7
 
How to Create a Toggle Button in Odoo 17
How to Create a Toggle Button in Odoo 17How to Create a Toggle Button in Odoo 17
How to Create a Toggle Button in Odoo 17Celine George
 
Protein Structure - threading Protein modelling pptx
Protein Structure - threading Protein modelling pptxProtein Structure - threading Protein modelling pptx
Protein Structure - threading Protein modelling pptxvidhisharma994099
 
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINT
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINTARTICULAR DISC OF TEMPOROMANDIBULAR JOINT
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINTDR. SNEHA NAIR
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...CaraSkikne1
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxraviapr7
 
Over the counter (OTC)- Sale, rational use.pptx
Over the counter (OTC)- Sale, rational use.pptxOver the counter (OTC)- Sale, rational use.pptx
Over the counter (OTC)- Sale, rational use.pptxraviapr7
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapitolTechU
 

Kürzlich hochgeladen (20)

How to Send Emails From Odoo 17 Using Code
How to Send Emails From Odoo 17 Using CodeHow to Send Emails From Odoo 17 Using Code
How to Send Emails From Odoo 17 Using Code
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptx
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
 
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdfP4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
P4C x ELT = P4ELT: Its Theoretical Background (Kanazawa, 2024 March).pdf
 
How to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 SalesHow to Manage Cross-Selling in Odoo 17 Sales
How to Manage Cross-Selling in Odoo 17 Sales
 
10 Topics For MBA Project Report [HR].pdf
10 Topics For MBA Project Report [HR].pdf10 Topics For MBA Project Report [HR].pdf
10 Topics For MBA Project Report [HR].pdf
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.
 
How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17How to Show Error_Warning Messages in Odoo 17
How to Show Error_Warning Messages in Odoo 17
 
KARNAADA.pptx made by - saransh dwivedi ( SD ) - SHALAKYA TANTRA - ENT - 4...
KARNAADA.pptx  made by -  saransh dwivedi ( SD ) -  SHALAKYA TANTRA - ENT - 4...KARNAADA.pptx  made by -  saransh dwivedi ( SD ) -  SHALAKYA TANTRA - ENT - 4...
KARNAADA.pptx made by - saransh dwivedi ( SD ) - SHALAKYA TANTRA - ENT - 4...
 
How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17How to Make a Field read-only in Odoo 17
How to Make a Field read-only in Odoo 17
 
Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...Patient Counselling. Definition of patient counseling; steps involved in pati...
Patient Counselling. Definition of patient counseling; steps involved in pati...
 
How to Create a Toggle Button in Odoo 17
How to Create a Toggle Button in Odoo 17How to Create a Toggle Button in Odoo 17
How to Create a Toggle Button in Odoo 17
 
Protein Structure - threading Protein modelling pptx
Protein Structure - threading Protein modelling pptxProtein Structure - threading Protein modelling pptx
Protein Structure - threading Protein modelling pptx
 
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINT
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINTARTICULAR DISC OF TEMPOROMANDIBULAR JOINT
ARTICULAR DISC OF TEMPOROMANDIBULAR JOINT
 
5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...5 charts on South Africa as a source country for international student recrui...
5 charts on South Africa as a source country for international student recrui...
 
Prescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptxPrescribed medication order and communication skills.pptx
Prescribed medication order and communication skills.pptx
 
Finals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quizFinals of Kant get Marx 2.0 : a general politics quiz
Finals of Kant get Marx 2.0 : a general politics quiz
 
Over the counter (OTC)- Sale, rational use.pptx
Over the counter (OTC)- Sale, rational use.pptxOver the counter (OTC)- Sale, rational use.pptx
Over the counter (OTC)- Sale, rational use.pptx
 
CapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptxCapTechU Doctoral Presentation -March 2024 slides.pptx
CapTechU Doctoral Presentation -March 2024 slides.pptx
 

Presentation parkinson

  • 1. CURRENT AND FUTURE OPTIONS FOR THE TREATMENT OF DYSKINESIA AND MOTOR FLUCTUATIONS IN PARKINSON’S DISEASE Guided by: Dr. Suneela Dhaneshwar Professor Presented by: Latika Budhalakoti M. Pharm (Pharmaceutical Chemistry) Department of Pharmaceutical Chemistry Bharati Vidyapeeth Deemed University Poona College of Pharmacy Erandwane, Pune-411038 1
  • 2.  Parkinson’s Disease (PD) A degenerative and progressive disorder.  Associated with neurological consequences of decreased dopamine levels produced by the basal ganglia (substantia nigra).  Dopamine (DOPA) is a neurotransmitter found in the neural synapses in the brain.  Initiates movement, expression. speech and self2
  • 3. Role of substantia nigra in Parkinson's disease. 3
  • 4. Causes  Environmental – toxins.  Free Radicals – there is a increase in post- mortem brain sections.  Aging – age related decline in dopamine production.  Genetic – possible, no single gene identified. 4
  • 6. Drugs for treatment of Parkinson’s disease  The Drugs:  Dopaminergic drugs (improving dopamine functioning) ○ Dopamine precursor- levodopa. ○ Dopamine receptor agonists- apomorphine. ○ NMDA receptor antagonist- amantadine.  Selective monoamine oxidase B inhibitors- selegiline.  Catechol-O-methyltransferase inhibitors- entacapone.  Antimuscarinic drugs (Ach inhibitors)-biperiden. 6
  • 7. Sites of action of drugs used to treat Parkinson's disease. + carbidopa Therapeutic effect 7
  • 9. Role of levodopa in Parkinson 9
  • 10. Limitations on use of levodopa      The response to L- DOPA changes during the progression. Thus total dosage and the total doses per day increases after intiation. Many patients exhibit abnormal involuntary movements (dyskinesia) and motor fluctuations. The use of levodopa may stimulate dopa receptors that can cause hallucinations, paranoia and confusion. L-DOPA is unable to halt the progresssion of neurodegeneration. 10
  • 11. Overcoming levodopa limitations  The risk of dyskinesia and motor fluctuations can be minimised o By improving methods of L-DOPA delivery. o By developing non - dopaminergic treatment methods. 11
  • 12.  In this article the current clinical management of motor complications are mentioned- o By peroral drug treatment. o By continuous dopaminergic stimulation or deep brain stimulation. 12
  • 13. Peroral drug therapy     The Dopamine agonists (DA) act on same receptors D3/ D4 but have longer duration of action than L-DOPA. The initial treatment may reduce dyskinesia and motor fluctuations. The Dopamine agonists added to l-dopa reduces time spent in “off condition”. Dopamine agonist is useful in advance condition of parkinson and motor fluctuations. 13
  • 14. Currently used DA in Parkinson’s disease 14
  • 15.  Dopamine agonists have disease modifying / neuroprotective effects.  On use of some biomarkers of presynaptic DA fibre it was found that there was slow loss of signal in patients treated than in l-dopa. o DOPAMINERGIC DRUG TREATMANT Includes COMT INHIBITORS, MAO-B INHIBITORS, NMDA RECEPTOR ANTAGONISTS.  15
  • 16.  COMT      INHIBITORS Are administered with l-dopa in patients with motor fluctuations. Prolongs the effect of single dose. Reduces the time spent in off state. Examples are tolcapone, entacapone. Side effect- it may cause hepatotoxicity. Tolcapone 16
  • 17. MAO- B Inhibitors       Rasagiline When added to LDOPA. Slows development of syptoms. Reduces l-dopa need. Reduces incidence of dyskinesias. Has disease modifying role. Rasagiline 17
  • 18. NMDA Receptor antagonists  Amantadine  Reduces l-dopa induced dyskinesia. It has potential to improve congenitive functions. It is an antidyskinetic agent.   Amantadine 18
  • 19.  The NMDA receptor is the only non dopaminergic drug currently used for l-dopa induced dyskinesia.  The NR2B subunit of the NMDA receptor is expressed in striatal neurons.  NMDA receptor antagonists that interact with NR2B subunit have shown to prevent development of dyskinesia in non human primate of parkinson disease. 19
  • 20. Continuous Dopaminergic stimulation (CDS)  Severe motor fluctuations are controlled by continuous dopaminergic stimulation.  Three types of interventions currently found effective areo Continuous deudenal l-dopa administration. o Subcutaneous apomorphine infusion. o Deep brain stimulation. o Continuous occupancy of DOPA receptors by long acting DOPA agonists. 20
  • 21.    o o  The intravenous administration of l-dopa for longer time was proved to be difficult. The first intraduodenal l-dopa infusion were published in 1986. L-DOPA-Carbidopa Intestinal Gel Combination of l-dopa(20mg/ml) and carbidopa and (5mg/ml). Is a pseudoplastic gel delivered through infusion pumps. LCIG infusion results in stabilization of both plasma l-dopa concentation and clinical status. 21
  • 22.  Reduction of motor fluctuations and time spent in off.  The mean dyskinesia severity was reduced by 90% over a period of 6 months of LICG therapy.  LCIG infusion improves non motor aspects (urological, git problems) of parkinson disease.  Initial duodenal LCIG infusion given only during day. 22
  • 23. Adverse events of LCIG infusion  Dislocation or occlusion of duodenal catheter.  Leakage in the infusion system.  Problems related to PEG establishment. 23
  • 24. Apomorphine treatment  Apomorphine (s.c.) administration along with ldopa exerts strongest on Parkinson disease.  It seems to be stable over long term follow up.  The probem associated with apomorphine infusion is formation of s.c. nodules.  The psychotic complications is not high with apomorphine than on dopaminergic therapy. 24
  • 25. Transdermal drug delivery  Recently developed method tried on DA agonists (rotigotine) to provide continuous drug supply and to treat advance stage of disease.  ADVANTAGES OF PATCH DELIVERY o When peroral delivery is contraindicated due to some GIT dysfunction. o In patients with therapy compliance problems. o In patients with parkinson related sleep disturbances in late night/early morning.  Side effects of rotigotine are skin reaction.  Lisuride and apomorphine are investigated to be given transdermally. 25
  • 26. Current surgical management of motor complications  Neurosurgery, including lesional surgery and deep brain stimulation are effective in advance parkinson.  Compared to deep brain stimulation the lesional surgery is associated with complications.  DEEP BRAIN STIMULATION (DBS) o Macromolecules are stereotactically implanted in brain part and is connected to electrical stimulator positioned subcutaneously in sub clavicular region. o Two brain nuclei most commonly used as target for DBS are globus pallidus and sub thalamic nucleus. 26
  • 27. Surgical interventions for Parkinson’s disease  Surgical intervention and description of procedureo Pallidotomy This involves the use of an electric probe to destroy a small portion of the brain that is overactive and is thought to cause the symptoms of PD. o Thalamotomy The procedure involves the removal of the thalamus in the brain, which is responsible for involuntary movements, thus destroying it prevents involuntary movements. This procedure is rarely performed and is only effective in providing relief from tremors. 27
  • 28.  Thalamic stimulation Involves the insertion of an electrode wire into the thalamus, the other end of which is connected to a pulse generator placed under the skin in the thorax. o The advantage is that it can produce the benefit of thalamotomy without causing incision of the skin and has demonstrated efficacy in the management of tremor in PD.  Deep brain stimulation (DBS) An alternative procedure used to destroy small regions of the brain. A thin electrode implanted into the brain prevents transmission of impulses for involuntary movements. 28
  • 29. Future treatment of Parkinson by gene therapy  By implanting genetically modified cells (ex vivo gene transfer).  By viral vector mediated gene delivery to resident cells( in vivo gene transfer). 29
  • 30. Gene therapy to provide continuous dopamine stimulation 30
  • 31. Treatment targeting non dopaminergic systems     o The addition of non dopaminergic drugs to ldopa prevents and treats motor complications. Reduces severity of peak dose dyskinesia. Prolong the time spent in “on” condition upon ldopa dosing. GLUTAMATE RECEPTORS Alter the synaptic and molecular level striatal neurons that occurs in dyskinetic animals. 31
  • 32. Tamarind used to treat Parkinson’s disease  A compound from tamarind tree help spur the growth of damaged brain andspinal cord nerve cells, which characterises Parkinson’s.  Xyloglucon , the extract from tamarind seeds. It’s a gel kind which will be helpful in regenerating the nerve cells.  On injection creates a favourable environment in the body to regenerate the cells. Thus in the human beings it is helpful to the production of Astrocytes which are responsible for the regeneration of the cells. 32
  • 33. Conclusion      Parkinson’s is a disease of the basal ganglia as well as neurotransmitter deficiencies. Significant advances have been made in optimizing strategies for continuous dopa stimulation in Parkinson’s. Continuous dopa stimulaion does not worsen condition of patient and even improve non motor features. Novel approaches to CDS based on gene therapy are being explored in parkinson patients. The results of this study will provide guidelines for designing clinical trials of antidyskinetic treatment. 33
  • 34. References  Mercuri, N . B.; Bernardi, G. The magic of l-dopa: why is it the gold standard Parkinson’s disease therapy? Trends Pharmacol. Sci., 2005, 26, 341-344.  Hoehn, M.M. Parkinson’s disease: progression and mortality. Adv. Neurol., 1987 , 45 , 457-461.  Ahlskog, J . E; Muenter , M .D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Discord., 2001 ,16, 448-458.  Schrag, A. Psychiatric aspects of Parkinson’s diseasean update. J. Neurol., 2004, 251, 795-804. 34